NKTR-102 145 mg/m2
11-PIR-09
Phase 2 small_molecule completed
Quick answer
NKTR-102 145 mg/m2 for Malignant Solid Tumor is a Phase 2 program (small_molecule) at NEKTAR THERAPEUTICS with 1 ClinicalTrials.gov record(s).
Program details
- Company
- NEKTAR THERAPEUTICS
- Indication
- Malignant Solid Tumor
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed